Lead Investigator: Anne-Marie Wills, Massachusetts General Hospital
Title of Proposal Research: Predictors of Progressive Supranuclear Palsy (PSP) disease progression using “A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)” (ClinicalTrials.gov ID NCT02985879)
Vivli Data Request: 9077
Funding Source: None
Potential Conflicts of Interest: None
Summary of the Proposed Research:
Progressive Supranuclear Palsy (PSP) is a rare disorder related to Parkinson’s disease and Frontotemporal Dementia affecting approximately 2-3/100,000 persons in the US. It is a neurological disease that causes impaired eye movements, speech, balance and falls and rapidly progresses to disability and death. There are currently no treatments for PSP and very few studies using patient reported outcomes measures in PSP. The PSP- Quality of Life scale (PSP-QoL) was first published in 2006, however there have been no studies looking at how the scale changes over time. Importantly, the PSP-QoL has not been compared to the validated PSP Rating Scale except in a small single center cross-sectional cohort study. Validating the PSP-QoL as a patient-reported outcome measure would be extremely important for developing new treatments for this disease.
Requested Studies:
An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)
Data Contributor: AbbVie
Study ID: NCT03391765
Sponsor ID: M15-563